Participants with Mild to Moderate Hidradenitis Suppurativa Will Receive EVO101 a Topical Cream 0.1%
Part of paid clinical trials in Norfolk, Virginia.
- Sponsor
- Virginia Clinical Research, Inc.
- Study ID
- NCT06645821
- Phase
- EARLY_PHASE1
- Status
- Recruiting
Conditions
- Hidradenitis Suppurativa (HS)
Eligibility Criteria
- Sex
- ALL
- Age
- 18 Years - N/A
- Healthy Volunteers
- Not accepted
Interventions
- EVO101 — DRUGEVO101 topical cream 0.1%
Study Details
The goal of this clinical trial is to learn if drug EVO101 works to treat mild to moderate hidradenitis suppurativa in adults. The main questions it aims to answer are: Does drug EVO101 lower the total number of lesion a participant has from the first visit to the last visit. What medical problems do participants have when applying drug EVO101 Does a participant perceive a change in their hidradenitis suppurativa symptoms based on patient reported outcome questionnaires. Participants will: Apply EVO101 topical cream 0.1% topically Visit the clinic four times unless the first and second appointment have to be done separately then there will be five clinic visits and one phone call over a twelve week period. Keep a dosing diary
Key Dates
- Start date
- Dec 3, 2024
- Status verified
- Dec 2024
- Primary completion
- Mar 31, 2025
- Completion
- May 31, 2025
Study Design
- Enrollment
- 15 participants (estimated)
- Allocation
- NA
- Intervention model
- SINGLE_GROUP
- Primary purpose
- TREATMENT
Arms
- Experimental: Open label EVO101 topical cream 0.1%All eligible subjects will receive open label EVO101 topical cream 0.1%
Primary Outcome Measure
The efficacy of EVO101 on hidradenitis suppurativa will be evaluated using two parameters: decrease in lesion count and change in patient reported outcomes (PRO) [ Time Frame: 12 Weeks ]
Central Contacts
- David M Pariser, MD757-625-0151
- Danielle L Benedict757-625-0151
Locations (1)
| Facility | City | State | ZIP | Site coordinators |
|---|---|---|---|---|
| Virginia Clinical Research, Inc. | Norfolk | Virginia | 23502 | David M Pariser, MD |
Find similar trials in Norfolk, VA
Related Studies
- Rollover Study for Participants Previously Enrolled in Clinical Trials of PovorcitinibPHASE3 · Recruiting · Incyte Corporation · Birmingham, Alabama
- Tibulizumab Skin Healing and Inflammation Evaluation for Lasting DefensePHASE2 · Recruiting · Zura Bio Inc · Phoenix, Arizona
- A Long-Term Follow-Up Observational Study to Evaluate Safety in Subjects Who Have Received a Gene-Modified Regulatory T Cell (Treg) TherapeuticRecruiting · Sonoma Biotherapeutics, Inc. · San Francisco, California
- 1726-nm Laser for Acne Inversa (Hidradenitis Suppurativa)PHASE1 · Recruiting · Wynn Medical Center · Rosemead, California